Radius Health (RDUS) Receives a Hold from Morgan Stanley

Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Radius Health (RDUSResearch Report) today and set a price target of $18.00. The company’s shares closed last Wednesday at $14.55.

According to TipRanks.com, Purohit has 0 stars on 0-5 stars ranking scale with an average return of -27.8% and a 16.0% success rate. Purohit covers the Healthcare sector, focusing on stocks such as Theravance Biopharma, Axsome Therapeutics, and Kymera Therapeutics.

Radius Health has an analyst consensus of Hold, with a price target consensus of $22.80.

See the top stocks recommended by analysts >>

The company has a one-year high of $26.16 and a one-year low of $11.95. Currently, Radius Health has an average volume of 383.9K.

Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RDUS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes abaloparatide transdermal patch for potential use in osteoporosis and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Waltham, MA.